La Jolla Pharmaceutical Co

LJPCCIK 0000920465 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K/A filed May 2, 2022. Sentiment + YoY language diff vs prior year. Read sections →

Signal:NeutralFull-doc fallback

Full filing:tone 0.0016

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

YoY shift: Unscored

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at La Jolla Pharmaceutical Co

Name	Roles	Filings
Rosen Robert	Director	1
Tang Kevin C	Director10% Owner	1

Showing 6-7 of 7

Per pagePrevPage 2 of 2

All filings

27 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
Jun 17, 2022	Hearne Michael S Chief Financial Officer	AGrant	236	$2.72	$642
Jun 2, 2022	Hearne Michael S Chief Financial Officer	AGrant	189	$3.4085	$644
May 17, 2022	Hearne Michael S Chief Financial Officer	AGrant	188	$3.4085	$641
May 3, 2022	Hearne Michael S Chief Financial Officer	AGrant	185	$3.468	$642
Apr 18, 2022	Hearne Michael S Chief Financial Officer	AGrant	173	$3.7145	$643

Showing 1-5 of 27

Per pagePage 1 of 6Next

Real-time Form 4 intelligence. Smarter insider tracking.

Filed		Top transaction	Shares	Price	Value